title: Retained role of surgery for olfactory neuroblastoma.
abstract: BACKGROUND
  Olfactory neuroblastoma is a rare paranasal sinus malignancy. The traditional approach was craniofacial resection (CFR) and then postoperative radiotherapy until 1998. This review will chart development of a new protocol.
  
  
  METHODS
  This ethics-approved audit evaluated the number of new patients diagnosed with olfactory neuroblastoma, with information relating to patient, disease, and treatment factors noted.
  
  
  RESULTS
  There were 24 eligible patients, 16 men, 8 women, 7 Kadish stage B, 17 stage C. The planned treatment was: chemotherapy (cisplatin/etoposide) and determine treatment dependent on response in 6 patients, surgery and radiotherapy in 16 patients, and single-modality treatment only (surgery, radiotherapy 1) in 2 patients. Surgery to radiotherapy occurred in 17 patients. With salvage treatment ultimate local control was 79%.
  
  
  CONCLUSIONS
  There was a higher local control in those patients who had surgery; abandoning this may carry a higher risk of local failure. The use of response to chemotherapy to determine local treatment remains experimental.
authors.affiliation: Department of Radiation Oncology, The Prince of Wales Cancer Centre, Randwick, New South Wales, Australia. robert.smee@sesiahs.health.nsw.gov.au
authors.forename: Robert I
authors.initials: RI
authors.lastname: Smee
authors.forename: Kathryn
authors.initials: K
authors.lastname: Broadley
authors.forename: Janet R
authors.initials: JR
authors.lastname: Williams
authors.forename: Nicola S
authors.initials: NS
authors.lastname: Meagher
authors.forename: G Patrick
authors.initials: GP
authors.lastname: Bridger
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D054869:Clinical Audit; D002985:Clinical Protocols; D018304:Esthesioneuroblastoma, Olfactory / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity / Q000473:pathology / Q000601:surgery*; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D009669:Nose Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D050397:Radiotherapy, Intensity-Modulated; D055815:Young Adult
chemical_list: D005047:Etoposide; D002945:Cisplatin